Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements examine discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CX